Our Investments

Developing a 483-acre data-center campus on Georgia's I-20 corridor, delivering up to 1.4 GW of compute for hyperscalers and AI companies on 15-year triple-net leases. Adjacent to Meta's data center and a 9M sq ft Rivian plant under construction. Targeting a ~$1B IPO on NASDAQ or NYSE.

Clinical-stage biotech advancing next-generation personalised cancer immunotherapy. FDA RMAT-designated, Phase 3-ready platform leveraging genetic and cellular technologies to enhance the immune response against tumours.

Pioneering robotic surgical technologies enabling complex procedures through smaller access points with greater precision and control. FDA Breakthrough Device designation, redefining the standard for minimally invasive surgery.

Advancing Emeramide (Irminix®) in Phase 2 clinical trials targeting Progressive Supranuclear Palsy and Parkinson's disease, addressing serious unmet needs in rare neurodegenerative conditions.

Healthcare services platform with $3.25M raised and $65M in claims receivables, optimising specialty care delivery and administrative efficiency across multiple service lines in North America.

Global leader in advanced wound care, co-founded by Dr. Harry Jacobson. Achieved a 12,882x MOIC and 50.7% gross IRR across two IPOs and two LBOs before a landmark $6.2B exit to Apax Partners.

One of the largest US dialysis providers, serving 32,500+ patients across 65 physician-led programmes. Acquired by Fresenius for $4B in 2006 after 40 consecutive quarters of growth and a 28% revenue CAGR.

Pioneer in radiology benefits management, securing a national at-risk contract with Aetna. Evolved into eviCore and acquired by ExpressScripts for $3.6B, returning $324.6M on a $7.5M investment.

Developer and operator of advanced diagnostic imaging centres in partnership with major health systems and Academic Health Centers. Sold to IVC Partners in 2018 at a 7.1x MOIC and 29.2% IRR.